RxDoctor Payments Data

Brandi Schwartz, APRN

Family · Louisville, KYNPI 1164149746

Payments from drug & device makers

$1,986in general payments, 2019–2025

Across 119 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$432
  • Exact Sciences$319
  • Novo Nordisk$267
  • Pfizer$172
  • Boehringer Ingelheim$141
  • GSK$111
  • plus $544 from 12 others

What the payments were for

  • Food & beverage$1,986100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,986 in reported general payments places this provider in the 75th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$55,628
Medicare patients
157
Services billed
656

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin15$19,291
FarxigaDapagliflozin Propanediol28$16,984
EliquisApixaban15$13,916
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$12,004
Atorvastatin Calcium160$1,375
Albuterol Sulfate HfaAlbuterol Sulfate48$1,132
Levothyroxine Sodium67$662
Potassium Chloride21$637
SynthroidLevothyroxine Sodium11$572
Fluticasone Propionate41$551
Rosuvastatin Calcium24$462
Duloxetine Hcl13$420
Pantoprazole Sodium15$400
Omeprazole58$375
Losartan Potassium23$353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$47$28,98841 claims
Boehringer IngelheimJardiance$141$19,29115 claims
PfizerEliquis$172$13,91615 claims
AbbVieSynthroid$432$57211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,374 family providers in Kentucky.

Other family in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →